Crinetics Pharmaceuticals
CRNX | NASDAQ
$84.95
$0.00 (0.00%)
At close: Aug 31, 2026, 4:00 PM ET
Crinetics Pharmaceuticals Company Profile
Company profile explainedCompany Profile
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Key Executives
| Name | Position |
|---|---|
| R. Scott Struthers | Founder, President, Chief Executive Officer & Director |
| Garlan Adams | Chief Legal Officer & Corporate Secretary |
| Kea Lingo | Chief Information Officer |
| Tobin C. Schilke | Chief Financial Officer |
| Adriana Cabre | Chief Human Resources Officer |
| Alan S. Krasner | Chief Endocrinologist |
| Chris Robillard | Chief Business Officer |
| Gayathri Diwakar | Head of Investor Relations |
| Kevin Capps | Head of Intellectual Property |
| Natalie Badillo | Head of Corporate Communications |
| Stephen F. Betz | Co-Founder & Chief Scientific Officer |
Crinetics Pharmaceuticals
| Country | United States |
| IPO Date | Jul 18, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 594 |
| CEO | R. Scott Struthers |
Contact Details
6055 Lusk Boulevard San Diego,
California 92121 United States
Stock Details
| Ticker Symbol | CRNX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001658247 |
| CUSIP Number | 22663K107 |
| ISIN Number | US22663K1079 |
| SIC Code | 2834 |
Recent News
- 4 months ago / zacks.comCrinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Tops Revenue Estimates
- 4 months ago / globenewswire.comCrinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
- 4 months ago / prnewswire.comAre CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders?
- 4 months ago / fool.comWhy This Pharmaceutical Stock Jumped Close to 100% This Week
- 4 months ago / 247wallst.comWhy Crinetics Stock Soared 99% This Week
- 4 months ago / zacks.comStrength Seen in CRINETICS PHARM (CRNX): Can Its 98.7% Jump Turn into More Strength?
- 4 months ago / newsfilecorp.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Crinetics Pharmaceuticals, Inc. (CRNX)
- 4 months ago / barrons.comSamsung, Micron, Rivian, SpaceX, Crinetics, and More Stocks That Explain Today's Market
- 4 months ago / businesswire.comCRNX Stock Alert: Halper Sadeh LLC is Investigating Whether Crinetics Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
- 4 months ago / benzinga.comCrinetics Pharmaceuticals Stock Doubles After The Close: Here's Why
Add to Watchlist
Select watchlists to add or remove CRNX